Welcome to our dedicated page for West Pharmaceutical Services news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharmaceutical Services stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a global leader in the design and manufacturing of innovative solutions for injectable drug administration systems. Headquartered in Exton, Pennsylvania, West collaborates closely with healthcare partners from concept to patient delivery, ensuring efficiency, reliability, and safety in packaging and delivery systems. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products, contributing approximately 80% of total revenue, include elastomer-based packaging components such as stoppers, seals, and plungers, as well as non-glass containment solutions and auto-injectors for injectable drugs. The Contract-Manufactured Products segment, accounting for the remaining 20%, focuses on manufacturing components for drug-injection devices and healthcare diagnostic devices.
West's commitment to cutting-edge technology, quality systems, and global regulatory compliance has positioned it as a key supplier to the pharmaceutical, biotechnology, and generic drug industries. The company supports its customers through sales, manufacturing, and research and development locations across North and South America, Europe, Asia, and Australia.
In recent financial results, West reported a solid performance despite the expected decline in COVID-19 related sales. The second-quarter and third-quarter 2023 showed a decline in net sales for Proprietary Products primarily due to reduced pandemic-related demand. However, the Contract-Manufactured Products segment demonstrated strong growth, with net sales increasing significantly. For the full-year 2023, West experienced challenges with headwinds from lower pandemic-related sales but saw gains in high-value product components and devices, as well as contract manufacturing.
West continues to innovate, recently expanding its administration systems portfolio with the FDA-cleared Vial2Bag Advanced® 13mm admixture device, enhancing drug preparation and delivery options at the point-of-care. As the company celebrates its 100-year milestone, it remains focused on meeting customer demand and investing in high-value products and manufacturing capacity to fuel future growth.
For more detailed information about West's latest financial performance and strategic initiatives, visit the company's official website.
West Pharmaceutical Services reported a strong second quarter in 2021, with net sales of $723.6 million, a growth of 37.3%. Organic sales growth was 30.6%, and diluted EPS rose to $2.47, marking a 104% increase. The company raised its full-year 2021 net sales guidance to $2.760-$2.785 billion and adjusted-diluted EPS guidance to $8.05-$8.20. The growth was driven by demand for high-value product components, particularly related to COVID-19 vaccines. Operating cash flow reached $233.1 million, reflecting a 13.6% increase.
West Pharmaceutical Services (NYSE: WST) will announce its second-quarter 2021 financial results on July 29, 2021, prior to market opening. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time featuring a discussion on results and business outlook. Interested participants can join the call by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 3089097. An online archive will be accessible on the company’s website for future reference.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 PM ET. A live broadcast of the event can be accessed on their website in the 'Investors' section. West has nearly 10,000 employees across 50 locations and generated over $2.15 billion in sales in 2020. The company is a trusted partner to drug developers, delivering over 40 billion components annually.
West Pharmaceutical Services has declared a third-quarter 2021 dividend of $0.17 per share, scheduled for payment on August 4, 2021, to shareholders recorded as of July 21, 2021. This dividend reflects the company's ongoing commitment to return value to its shareholders. Additionally, management will present a business overview at the Bank of America Securities 2021 Healthcare Conference on May 11, 2021, at 2:45 p.m. EDT. West generated over $2.15 billion in sales in fiscal year 2020.
West Pharmaceutical Services reported impressive Q1 2021 results with net sales of $670.7 million, a 36.5% year-over-year increase. Diluted EPS rose 101% to $1.99, while adjusted-diluted EPS climbed 103% to $2.05. The company has raised its full-year net sales guidance to $2.630 billion - $2.655 billion from a previous range of $2.500 billion - $2.525 billion. This growth is attributed to strong organic sales driven by demand for COVID-19 related products and robust performance in the Proprietary Product Segment.
West Pharmaceutical Services, a leader in injectable drug administration, will release its first-quarter 2021 financial results on April 29, 2021, before the market opens. A conference call to discuss these results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International), using Conference ID 4285757. The call will be available for live broadcast on their website and archived for later access until May 6, 2021.
West Pharmaceutical Services, traded under the ticker WST, will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 10:00 AM ET. The presentation will be accessible via a live audio webcast on their website. West is known for providing high-quality injectable solutions and services, boasting nearly 10,000 employees and generating over $2.15 billion in sales in 2020. The company is headquartered in Exton, Pennsylvania, and is included in the Standard & Poor's 500 index.
West Pharmaceutical Services, Inc. (NYSE: WST) has announced a second-quarter 2021 dividend of $0.17 per share. This dividend will be paid on May 5, 2021, to shareholders recorded as of April 21, 2021. The company, which generated over $2.15 billion in sales in fiscal year 2020, is recognized as a leading provider of injectable solutions and services. With nearly 10,000 employees globally, West plays a crucial role in ensuring the safe delivery of vital medicines.
West Pharmaceutical Services reported strong Q4 and full-year 2020 results, with Q4 net sales of $580.2 million, a 23.3% increase, and full-year net sales of $2.147 billion, up 16.7%. Q4 diluted EPS rose 53.6% to $1.29, while full-year EPS jumped 42.4% to $4.57. The company forecasts 2021 net sales between $2.500 billion and $2.525 billion and EPS of $6.00 to $6.15. Strong sales growth was driven by the Biologics and Generics segments, particularly high-value product components for COVID-19.
West Pharmaceutical Services (NYSE: WST) has announced its plan to release fourth-quarter and full-year 2020 financial results on February 18, 2021, before the market opens. A conference call will follow at 9:00 a.m. ET to discuss the results and future business expectations. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 4095168. A live broadcast and an online archive of the call will be available on the company's website.
FAQ
What is the current stock price of West Pharmaceutical Services (WST)?
What is the market cap of West Pharmaceutical Services (WST)?
What does West Pharmaceutical Services, Inc. specialize in?
Where is West Pharmaceutical Services headquartered?
What are the two main segments of West Pharmaceutical Services?
How much of West's revenue comes from international markets?
What recent products has West Pharmaceutical Services launched?
What are some of the key products offered by West Pharmaceutical Services?
How did West Pharmaceutical Services perform in the latest financial quarters?
What are West Pharmaceutical Services' long-term growth strategies?
How does West Pharmaceutical Services support its customers globally?
Where can I find more information about West Pharmaceutical Services?
